Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Kidney cancer
Belzutifan (HIF-2α inhibitor) + lenvatinib holds HRQoL steady vs cabozantinib in post–PD-(L)1 RCC
Belzutifan (a first-in-class oral HIF-2α inhibitor) plus lenvatinib (a VEGFR/FGFR multikinase TKI) was compared with cabozantinib (VEGFR/MET/AXL TKI) in the open-label Phase 3 LITESPARK-011 trial (NCT04586231) in…
NCT04586231 - Trial result
Kidney cancer
Tivozanib (VEGFR TKI) Beats Tivozanib+Nivolumab in Post-ICI mRCC PFS (No OS Gain)
Tivozanib (Tivo) is an oral, selective VEGFR tyrosine kinase inhibitor; TiNivo-2 (Phase 3; NCT04987203) tested ICI rechallenge by adding nivolumab (anti–PD-1) to tivozanib versus tivozanib alone in metastatic RCC…
NCT04987203 - Trial result
Sarcoma and GIST
Lete-cel (NY-ESO-1 TCR-T) and afami-cel (MAGE-A4 TCR-T) show ~29–43% ORR in pediatric metastatic synovial sarcoma
Lete-cel is an engineered autologous TCR-T targeting NY-ESO-1 and afami-cel is an engineered autologous TCR-T targeting MAGE-A4; this pooled pediatric analysis across four Phase II studies (NCT01343043, NCT03967223,…
NCT01343043 - Trial result Spotlight
Neuroendocrine and adrenal tumors
Sacituzumab govitecan (TROP2–SN-38 TOP1 ADC) + berzosertib (ATR inhibitor) lifts disease control to 86% in platinum-refractory EPSCC
Berzosertib is an IV ATR (replication-stress response) inhibitor combined here with either conventional TOP1 inhibition (topotecan) or tumor-targeted TOP1 payload delivery via the TROP2-directed ADC sacituzumab…
NCT03896503 - Trial result
Head and neck cancer
TPF induction (docetaxel/cisplatin/5-FU) fails to beat PF adjuvant after CCRT in LA-NPC
TPF is a 3-drug cytotoxic induction regimen (taxane + platinum + fluoropyrimidine) given pre-radiation to debulk disease and reduce distant relapse risk; here it was tested as 3 cycles of TPF induction → IMRT +…
NCT03574324 - Trial result
Sarcoma and GIST
Catequentinib (AL3818) multitarget RTK inhibitor delivers 26.8% ORR with 18.3-mo mPFS in advanced ASPS (APROMISS)
Catequentinib hydrochloride (AL3818) is an oral multitargeted receptor tyrosine kinase inhibitor (anti-angiogenic TKI class) evaluated as monotherapy in the open-label, non-randomized ASPS cohort of the Phase 3…
NCT03016819 - Trial result Spotlight
Head and neck cancer
Emiltatug Ledadotin B7-H4 ADC Reaches 40% ORR in Aggressive ACC
Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4–directed ADC with an auristatin F-HPA microtubule-inhibitor payload, evaluated in a Phase 1 dose-escalation/backfill cohort enriched for aggressive adenoid cystic…
NCT05377996 - Trial result
Head and neck cancer
Pembrolizumab (PD-1) + Docetaxel/Doxorubicin Delivers Modest Responses in Advanced Salivary/Thyroid Cancers
Pembrolizumab is an anti–PD-1 immune checkpoint inhibitor combined here with cytotoxic chemotherapy (docetaxel or doxorubicin) in the single-center, parallel-cohort iPRIME study (Phase 2–like design; NCT03360890) for…
NCT03360890 - Trial result
Head and neck cancer
AVA6000 FAP-Released Doxorubicin Posts 90% Disease Control in Salivary Gland Cancer
AVA6000 is a fibroblast activation protein-cleavable peptide-drug conjugate designed to release doxorubicin preferentially in the tumor microenvironment. In the first-in-human Phase Ia/Ib trial (NCT04969835), the…
NCT04969835 - Trial result
Head and neck cancer
Darolutamide + Leuprolide Yields 40% PR Rate in AR+ Salivary Gland Cancer
Darolutamide is a nonsteroidal androgen-receptor inhibitor, combined here with leuprolide acetate to deepen androgen-axis suppression in hormone-therapy-naïve recurrent/metastatic or unresectable AR+ salivary gland…
NCT05669664 - Trial result
Head and neck cancer
REM-422 MYB mRNA Degrader Hits 42% ORR at RP2D in MYB+ ACC
REM-422 is a first-in-class oral small-molecule MYB mRNA degrader tested in recurrent/metastatic adenoid cystic carcinoma in the Phase 1/2 ARIA trial (NCT06118086). Among efficacy-evaluable patients (n=59), activity…
NCT06118086 - Trial result
Head and neck cancer
Pemetrexed + pembrolizumab (antifolate chemo + PD-1) posts 75% clinical benefit but just 5% ORR in R/M adenoid cystic carcinoma
Pemetrexed (PTX; multitargeted antifolate chemotherapy) plus pembrolizumab (PMB; PD-1 inhibitor) was evaluated in the MC200708 single-arm Phase II trial (NCT04895735) in recurrent/metastatic adenoid cystic carcinoma…
NCT04895735 - Trial result Spotlight
Multiple myeloma
DaraKPd (anti-CD38 mAb + proteasome inhibitor + IMiD) delivers 38.3-mo mPFS in CD38-naïve RRMM
Daratumumab (anti-CD38 monoclonal antibody) combined with carfilzomib (proteasome inhibitor), pomalidomide (IMiD), and dexamethasone (DaraKPd) was evaluated in a phase 2 MMRC study in relapsed/refractory multiple…
NCT01665794 - Trial result Spotlight
Multiple myeloma
Durcabtagene autoleucel (PHE885), a rapid-manufactured BCMA CAR-T, posts 98% ORR and 55% sCR in r/r multiple myeloma
Durcabtagene autoleucel (also known as PHE885) is an autologous BCMA-directed CAR-T made on a rapid manufacturing platform intended to preserve stem-like T-cell features. In Part A of a Phase 1, dose-escalation study…
NCT04318327 - Trial result
Multiple myeloma
Daratumumab (CD38 mAb) boosts depth of response across age/frailty in TIE NDMM (MAIA/CEPHEUS)
Daratumumab is an anti-CD38 monoclonal antibody added to immunomodulatory backbone Rd (MAIA; DRd vs Rd; n=368 vs 369) or to proteasome-inhibitor triplet VRd (CEPHEUS; DVRd vs VRd; n=144 vs 145) in…
- Trial result
Multiple myeloma
Isa SC (on-body injector) + VRd Cuts Infusion Reactions and Neuropathy vs IV Isa-VRd, with Similar ≥VGPR in Ti NDMM (8-mo follow-up)
Isatuximab (anti-CD38 monoclonal antibody) + VRd was given either subcutaneously via an on-body injector (Isa OBI VRd; ISASOCUT Phase 2, n=74; weekly bortezomib after C1) or intravenously (Isa IV VRd; IMROZ Phase 3,…
- Trial result
Multiple myeloma
Daratumumab (CD38 mAb) + Rd Extends PFS to 61.9mo and Improves OS in MAIA NDMM
Daratumumab is an anti-CD38 monoclonal antibody added to lenalidomide (IMiD) + dexamethasone (D-Rd) and tested vs Rd in the Phase 3, randomized MAIA trial (NCT02252172) in transplant-ineligible newly diagnosed…
NCT02252172 - Trial result
Multiple myeloma
Ciltacabtagene autoleucel (cilta-cel) BCMA CAR-T delivers durable 30-month PFS/OS—even in high-risk cytogenetics with ≥PR bridging response
Ciltacabtagene autoleucel (cilta-cel) is an autologous anti-BCMA CAR-T cell therapy evaluated in CARTITUDE-4 (Phase 3; NCT04181827) for lenalidomide-refractory multiple myeloma after 1–3 prior lines; this as-treated…
NCT04181827 - Trial result
Multiple myeloma
Belantamab mafodotin (BCMA ADC) + VRd in DREAMM-9 delivers ≥83% ORR in transplant-ineligible NDMM, with dose-intensity–driven depth vs ocular toxicity tradeoff
Belantamab mafodotin (belamaf) is an anti-BCMA antibody–drug conjugate combined here with bortezomib/lenalidomide/dexamethasone (VRd) as BVRd in the DREAMM-9 Phase 1 dose/schedule optimization study in…
NCT04091126 - Trial result
Multiple myeloma
Talquetamab (GPRC5D×CD3) + teclistamab (BCMA×CD3) lands on Q2W RP2R with 61.1% ORR and 44.4% ≥CR in extramedullary MM
Talquetamab (Tal), a first-in-class GPRC5D-targeting T-cell–redirecting bispecific antibody, was combined with teclistamab (Tec), a first-in-class BCMA-targeting T-cell–redirecting bispecific, in the RedirecTT-1…
NCT04586426 - Trial result Spotlight
Acute myeloid leukemia and MDS
AZA/VEN + ivosidenib (IDH1 inhibitor) drives 95% ORR and 79% 3-year OS in unfit IDH1-mut AML
Azacitidine (DNA hypomethylating agent) + venetoclax (BCL-2 inhibitor) + ivosidenib (mutant IDH1 inhibitor) was evaluated as a frontline “triplet” in a multicenter Phase Ib/II study (NCT03471260) for newly diagnosed…
NCT03471260 - Trial result Spotlight
Acute myeloid leukemia and MDS
Mesutoclax (ICP-248), a selective BCL-2 inhibitor, drives 86% cCR with azacitidine in treatment-naïve AML
Mesutoclax (ICP-248) is a next-gen, highly selective BCL-2 inhibitor (positioned as a venetoclax-like backbone with a “cleaner” PK profile) tested with azacitidine in the ongoing global Phase 1 ICP-CL-01205…
NCT06656494 - Trial result
Acute myeloid leukemia and MDS
Quizartinib (FLT3 inhibitor) + decitabine/venetoclax drives 89% CR/CRi and 36.5-mo OS in older frontline FLT3-ITD AML
Quizartinib (QUIZ) is an oral, potent FLT3 inhibitor combined with decitabine (DNA hypomethylating agent) and venetoclax (BCL-2 inhibitor) in a Phase I/II study (NCT03661307) enrolling newly diagnosed FLT3-ITD AML…
NCT03661307 - Trial result
Acute myeloid leukemia and MDS
Revumenib (menin inhibitor; KMT2A/NPM1 program) maintenance post-alloSCT shows 89% 2-year OS with low 1-year relapse
Revumenib (Revuforj) is an oral menin inhibitor that disrupts the menin–KMT2A interaction and is FDA-approved (since November 15, 2024) for R/R acute leukemia with KMT2A rearrangement (≥1 year old); here it was used…
- Trial result
Acute lymphoblastic leukemia
Dose-dense mini–hyper-CVD + inotuzumab (CD22 ADC) + blinatumomab (CD19 BiTE) drives ~95% NGS-MRD negativity in R/R B-ALL, with better 2-year survival when consolidated with CAR-T/SCT
Dose-dense mini–hyper-CVD chemotherapy combined with inotuzumab ozogamicin (anti-CD22 calicheamicin ADC) and blinatumomab (CD19×CD3 bispecific T-cell engager) was evaluated in a Phase 2 study in adults with…
- Trial result
Acute lymphoblastic leukemia
Blinatumomab (CD19 BiTE) + ponatinib (BCR::ABL1 TKI) drives 83% CMR and 89% 3-year OS in frontline Ph+ B-ALL
Blinatumomab is a CD19-directed bispecific T-cell engager (BiTE) paired with ponatinib, a potent BCR::ABL1 tyrosine kinase inhibitor active against T315I, in an ongoing single-arm Phase II frontline study in newly…
NCT03263572 - Trial result
Acute lymphoblastic leukemia
Tisagenlecleucel (CD19 CAR-T) delivers 64% 5-year DFS in frontline MRD+ high-risk pediatric/AYA B-ALL
Tisagenlecleucel (tisa-cel) is an autologous CD19-directed CAR-T therapy tested in the global COG AALL1721/CASSIOPEIA Phase 2 trial (NCT03876769) for very high-risk NCI high-risk B-ALL with persistent MRD ≥0.01% by…
NCT03876769 - Trial result
Acute lymphoblastic leukemia
Olverembatinib (BCR::ABL1 TKI) + blinatumomab (CD19 BiTE) delivers early CR/MRD clearance in heavily pretreated Ph+ ALL/CML-LBP
Olverembatinib (HQP1351) is a third-generation BCR::ABL1 tyrosine kinase inhibitor (active against resistant clones including T315I) combined here with blinatumomab, a CD19×CD3 bispecific T-cell engager, in the Phase…
NCT04260022 - Trial result Spotlight
Chronic lymphocytic leukemia
Sonrotoclax (BCL2 inhibitor) + zanubrutinib (BTK inhibitor) drives 99% PB uMRD4 and 100% 30-mo PFS in 1L CLL/SLL
Sonrotoclax (BGB-11417) is a next-generation oral BCL2 inhibitor combined with the oral BTK inhibitor zanubrutinib in the Phase 1/1b BGB-11417-101 study (NCT04277637) in treatment-naive CLL/SLL (sonro 320 mg cohort;…
NCT04277637 - Trial result
Chronic lymphocytic leukemia
Liso-cel (CD19 CAR-T) delivers 84% ORR/55% CR in heavily pretreated R/R CLL (CIBMTR)
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR T-cell therapy evaluated in a US CIBMTR real-world observational cohort of commercial use (May 2024–Sep 2025) in R/R CLL (n=45), with patients…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.